CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS

Respirology ◽

10.1111/resp.13207_77 ◽

2017 ◽

Vol 22 ◽

pp. 114-114 ◽

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Clinical Analysis ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

Lung Cancer ◽

10.1016/j.lungcan.2016.01.018 ◽

2016 ◽

Vol 96 ◽

pp. 87-92 ◽

Author(s):

Jianlin Xu ◽

Bo Jin ◽

Tianqing Chu ◽

Xue Dong ◽

Haitang Yang ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non–small cell lung cancer harboring EGFR mutations

10.18632/oncotarget.19243 ◽

2017 ◽

Vol 8 (40) ◽

pp. 68123-68130 ◽

Author(s):

Kentaro Tanaka ◽

Kaname Nosaki ◽

Kohei Otsubo ◽

Koichi Azuma ◽

Shinya Sakata ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Resistance Mutation ◽

Egfr Mutations ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Download Full-text

Calpain4 Regulates The Response Of Non-Small Cell Lung Cancer Cell Lines To EGFR Tyrosine Kinase Inhibitor Erlotinib

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6288 ◽

2012 ◽

Author(s):

Sucheta Kulkarni ◽

Leya Saju ◽

Carol F. Farver

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Lung Cancer Cell ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Abstract 3802: Effect of CS-7017, a selective PPARδ agonist, on the TGFβ/Smad-mediated enhanced cell motility of EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

10.1158/1538-7445.am2012-3802 ◽

2012 ◽

Author(s):

Masakuni Serizawa ◽

Masaru Watanabe ◽

Junko Suzuki ◽

Akane Naruoka ◽

Haruyasu Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Motility ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-019-00887-0 ◽

2019 ◽

Vol 38 (3) ◽

pp. 874-884

Author(s):

Weiwei Tan ◽

Nagdeep Giri ◽

Susan Quinn ◽

Keith Wilner ◽

Kourosh Parivar

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Potential Effect ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8067 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8067-8067 ◽

Author(s):

Akito Hata ◽

Nobuyuki Katakami ◽

Hiroshige Yoshioka ◽

Katsuhiro Masago ◽

Shiro Fujita ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation

British Journal of Cancer ◽

10.1038/sj.bjc.6605748 ◽

2010 ◽

Vol 103 (3) ◽

pp. 347-353 ◽

Author(s):

Y Loriot ◽

P Mordant ◽

N Dorvault ◽

T De la motte Rouge ◽

J Bourhis ◽

...

Keyword(s):

Lung Cancer ◽

Synergistic Effect ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.12.023 ◽

2017 ◽

Vol 12 (5) ◽

pp. e46-e47 ◽

Author(s):

Hiroaki Ogata ◽

Yuzo Yamamoto ◽

Taishi Harada ◽

Yoichi Nakanishi ◽

Isamu Okamoto ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Aplastic Anemia ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer

Cancer Letters ◽

10.1016/j.canlet.2018.07.025 ◽

2018 ◽

Vol 434 ◽

pp. 152-159 ◽

Author(s):

Chun-Te Chiang ◽

Alexandra N. Demetriou ◽

Nolan Ung ◽

Niharika Choudhury ◽

Kimya Ghaffarian ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Metabolic Reprogramming ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text